GLP-1 Market
LLY $1137.82 ▲ +0.2% NVO $41.71 ▼ -1.9% PFE $27.46 ▼ -0.3% VKTX $29.52 ▼ -1.4% KLRA $12.70 ▼ -5.6% GPCR $35.50 ▼ -8.9% RHHBY $55.15 ▲ +0.4%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

ASC30 A1

ASC30 A1

Company
Ascletis Pharma (China) Co., Limited
Mechanism
Mechanism not yet reported
Route
Oral
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 17, 2026

Find a Clinical Trial Near Me

See recruiting studies for ASC30 A1 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07743450

    A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

    Not yet reported Ascletis Pharma (China) Co., Limited 1560 participants Est. completion 2028-07 135 sites Stand-alone
    Type 2 diabetes Other conditions: Obesity, Overweight, Chronic Weight Management
    View official trial listing →
  • Recruiting NCT NCT07743463

    A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

    Not yet reported Ascletis Pharma (China) Co., Limited 3003 participants Est. completion 2028-07 122 sites Stand-alone
    Other conditions: Obesity, Overweight, Chronic Weight Management
    View official trial listing →
  • Completed NCT NCT06680440

    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of ASC30 Tablets and ASC30 Tablets A1 in Participants With Obesity

    Not yet reported Ascletis Pharma (China) Co., Limited 72 participants Est. completion 2025-04-03 1 site
    Other conditions: Weight Management
    View official trial listing →
  • Completed NCT NCT07002905

    A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related Comorbidities

    Not yet reported Ascletis Pharma (China) Co., Limited 125 participants Est. completion 2025-12-08 6 sites Stand-alone
    Other conditions: Chronic Weight Management
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: ASC30 A1, ASC30 tablets A1

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.